Alaunos Therapeutics, Inc Financials
Alaunos Therapeutics, Inc (TCRT) reported $5K in revenue for fiscal year 2025, down 50.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing, not sales, is sustaining this development-stage operation after a sharp multi-year expense reset.
By FY2025, free cash burn had narrowed to-$3.0M from-$5.0M in the prior year. Cash still increased because financing inflows of$3.3M more than covered that burn, even though revenue was only$5K , which shows the business is still funded primarily by capital raising rather than by customers.
The main operating change is cost retrenchment, not commercial traction: R&D fell from
Recent losses have high cash fidelity; in FY2025, net loss was
Financial Health Signals
Alaunos Therapeutics, Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Alaunos Therapeutics, Inc scores -437.27, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($4.6M) relative to total liabilities ($813K). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Alaunos Therapeutics, Inc passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
Alaunos Therapeutics, Inc reported a net loss of $4.2M while operations used $2.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Alaunos Therapeutics, Inc generated $5K in revenue in fiscal year 2025. This represents a decrease of 50.0% from the prior year.
Alaunos Therapeutics, Inc's EBITDA was -$4.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 12.3% from the prior year.
Alaunos Therapeutics, Inc reported -$4.2M in net income in fiscal year 2025. This represents an increase of 10.8% from the prior year.
Alaunos Therapeutics, Inc earned -$2.20 per diluted share (EPS) in fiscal year 2025. This represents an increase of 24.7% from the prior year.
Cash & Balance Sheet
Alaunos Therapeutics, Inc recorded an outflow of $3.0M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 40.3% from the prior year.
Alaunos Therapeutics, Inc held $1.4M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Alaunos Therapeutics, Inc's ROE was -194.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 32.9 percentage points from the prior year.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Alaunos Therapeutics, Inc invested $1.4M in research and development in fiscal year 2025. This represents an increase of 276.5% from the prior year.
Alaunos Therapeutics, Inc invested $98K in capex in fiscal year 2025, funding long-term assets and infrastructure.
Not reported for fiscal year 2025.
TCRT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $5K-50.0% | $10K+100.0% | $5K-99.8% | $2.9M+634.2% | $398K-60.2% | $1.0M | N/A | $146K-99.1% | $15.9M+131.7% | $6.9M | N/A | N/A | N/A | $800K+19.9% | $667K |
| R&D Expenses | N/A | $1.4M+276.5% | $362K-97.8% | $16.3M-34.9% | $25.0M-49.6% | $49.6M-5.8% | $52.7M+37.5% | $38.3M+12.3% | $34.1M-24.3% | $45.1M-71.4% | $157.8M+47.8% | $106.8M+226.5% | $32.7M-23.7% | $42.9M-48.6% | $83.4M+46.2% | $57.1M |
| SG&A Expenses | N/A | $2.9M-35.7% | $4.5M-63.5% | $12.2M-7.0% | $13.1M-52.3% | $27.6M-0.4% | $27.7M+41.7% | $19.5M-2.0% | $19.9M+34.6% | $14.8M+2.9% | $14.4M-18.5% | $17.6M+45.1% | $12.2M-22.3% | $15.7M-19.8% | $19.5M+30.3% | $15.0M |
| Operating Income | N/A | -$4.2M+12.2% | -$4.8M+86.0% | -$34.3M+2.4% | -$35.1M+54.7% | -$77.5M+3.5% | -$80.4M-38.9% | -$57.9M-7.3% | -$53.9M-0.8% | -$53.5M+67.6% | -$165.3M-37.6% | -$120.1M-176.1% | -$43.5M+24.6% | -$57.7M+43.5% | -$102.2M-43.1% | -$71.4M |
| Interest Expense | N/A | N/A | $0-100.0% | $1.9M-39.1% | $3.2M+165.3% | $1.2M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$4.2M+10.8% | -$4.7M0.0% | -$4.7M+87.6% | -$37.7M+52.1% | -$78.8M+1.5% | -$80.0M+32.1% | -$117.8M-121.8% | -$53.1M+2.2% | -$54.3M+67.1% | -$165.3M-37.6% | -$120.1M-277.9% | -$31.8M+44.3% | -$57.1M+40.6% | -$96.1M-50.7% | -$63.8M |
| EPS (Diluted) | — | -$2.20+24.7% | -$2.92 | -$21.97 | -$2.61 | -$0.37+2.6% | -$0.38+45.7% | -$0.70-172.9% | $0.96+281.1% | -$0.53+59.8% | -$1.32 | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
TCRT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.0M+7.7% | $2.8M-66.7% | $8.3M-87.3% | $64.9M-31.5% | $94.9M-35.2% | $146.3M+34.1% | $109.1M+14.8% | $95.1M-10.0% | $105.6M-0.7% | $106.3M-30.8% | $153.7M+239.8% | $45.2M-37.0% | $71.8M-14.0% | $83.4M-22.9% | $108.1M |
| Current Assets | $2.0M-27.8% | $2.8M-66.7% | $8.3M-84.6% | $53.8M-31.8% | $78.8M-39.6% | $130.6M+23.8% | $105.5M+25.2% | $84.3M-7.2% | $90.8M-13.4% | $104.9M-31.2% | $152.5M+246.0% | $44.1M-37.3% | $70.3M-12.4% | $80.3M-24.3% | $106.1M |
| Cash & Equivalents | $1.4M+26.9% | $1.1M-82.0% | $6.1M-84.5% | $39.1M-48.6% | $76.1M-33.9% | $115.1M+44.3% | $79.7M+29.2% | $61.7M-13.0% | $70.9M-12.5% | $81.1M-42.4% | $140.7M+228.8% | $42.8M-37.2% | $68.2M-7.0% | $73.3M-30.0% | $104.7M |
| Total Liabilities | $813K+17.5% | $692K-64.6% | $2.0M-92.6% | $26.4M-28.3% | $36.8M+64.6% | $22.4M+58.6% | $14.1M+48.7% | $9.5M-95.3% | $202.4M+10.2% | $183.6M+176.8% | $66.4M+482.2% | $11.4M-49.1% | $22.4M-36.0% | $35.0M-4.2% | $36.5M |
| Current Liabilities | $813K+17.5% | $692K-64.6% | $2.0M-91.9% | $24.2M+50.7% | $16.0M-12.7% | $18.4M+46.6% | $12.5M+32.1% | $9.5M-54.5% | $20.9M+31.9% | $15.8M-12.8% | $18.1M+67.4% | $10.8M+39.0% | $7.8M-58.7% | $18.9M+41.2% | $13.4M |
| Long-Term Debt | N/A | $0 | $0 | $0-100.0% | $16.3M | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $2.2M+4.4% | $2.1M-67.3% | $6.3M-83.6% | $38.6M-33.6% | $58.1M-53.2% | $124.0M+30.5% | $95.0M+11.0% | $85.6M+188.4% | -$96.8M-25.2% | -$77.3M-188.5% | $87.4M+158.2% | $33.8M-31.5% | $49.4M+1.9% | $48.4M-32.3% | $71.6M |
| Retained Earnings | -$924.6M-0.5% | -$920.4M-0.5% | -$915.8M-4.0% | -$880.6M-4.5% | -$842.9M-10.3% | -$764.1M-11.7% | -$684.1M-20.8% | -$566.3M+20.5% | -$712.4M-8.3% | -$658.0M-33.5% | -$492.7M-32.2% | -$372.6M-9.3% | -$340.8M-20.1% | -$283.7M | N/A |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
TCRT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.7M | -$2.9M+42.3% | -$5.0M+83.5% | -$30.1M-3.1% | -$29.2M+52.4% | -$61.5M-7.8% | -$57.0M-39.6% | -$40.9M+17.4% | -$49.5M+9.5% | -$54.7M+6.3% | -$58.3M-583150.0% | -$10K+100.0% | -$36.6M+38.4% | -$59.5M+24.5% | -$78.8M-103.0% | -$38.8M |
| Capital Expenditures | N/A | $98K | $0-100.0% | $197K-8.8% | $216K-93.5% | $3.3M-66.0% | $9.8M+3343.0% | $284K-38.1% | $459K-37.7% | $737K+33.8% | $551K+33.7% | $412K+113.5% | $193K+46.2% | $132K-91.5% | $1.6M+34.9% | $1.2M |
| Free Cash Flow | N/A | -$3.0M+40.3% | -$5.0M+83.6% | -$30.3M-3.0% | -$29.4M+54.5% | -$64.8M+3.0% | -$66.8M-62.4% | -$41.1M+17.6% | -$49.9M+9.9% | -$55.4M+5.9% | -$58.9M-13851.7% | -$422K+98.9% | -$36.8M+38.2% | -$59.6M+25.8% | -$80.4M-101.0% | -$40.0M |
| Investing Cash Flow | N/A | -$98K | $0-100.0% | $1.3M+797.4% | -$193K+94.2% | -$3.3M+66.0% | -$9.8M-3343.0% | -$284K+38.1% | -$459K+37.7% | -$737K-33.8% | -$551K | N/A | N/A | -$131K+91.6% | -$1.6M-34.9% | -$1.2M |
| Financing Cash Flow | N/A | $3.3M | $0+100.0% | -$18.1M-384.9% | $6.4M-75.3% | $25.8M-74.8% | $102.1M+72.6% | $59.1M+46.7% | $40.3M-11.0% | $45.3M+5848.6% | -$788K | N/A | N/A | $54.5M+11.3% | $49.0M-41.9% | $84.3M |
| Share Buybacks | N/A | N/A | N/A | $0-100.0% | $45K | $0 | N/A | $653K-59.7% | $1.6M | $0-100.0% | $2K-94.1% | $34K-93.8% | $544K+9.2% | $498K-8.8% | $546K+99.3% | $274K |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
TCRT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -84500.0% | -48120.0% | -685340.0% | -1201.4% | -19484.7% | -8036.1% | N/A | -36921.9% | -336.4% | -2409.4% | N/A | N/A | N/A | -12771.1% | -10704.6% |
| Net Margin | -83520.0% | -46790.0% | -93580.0% | -1291.2% | -19786.7% | -7997.6% | N/A | -36381.5% | -341.7% | -2409.2% | N/A | N/A | N/A | -12016.5% | -9561.9% |
| Return on Equity | -194.0%+32.9pp | -226.8%-152.6pp | -74.2%+23.7pp | -97.9%+37.8pp | -135.6%-71.1pp | -64.5%+59.5pp | -124.0%-61.9pp | -62.1% | N/A | N/A | -137.5%-43.5pp | -93.9%+21.7pp | -115.6%+82.8pp | -198.4%-109.4pp | -89.1% |
| Return on Assets | -140.8%+29.0pp | -169.8%-113.2pp | -56.6%+1.5pp | -58.1%+24.9pp | -83.0%-28.4pp | -54.6%+53.3pp | -108.0%-52.1pp | -55.9%-4.4pp | -51.4%+104.0pp | -155.4%-77.3pp | -78.1%-7.9pp | -70.3%+9.3pp | -79.6%+35.7pp | -115.3%-56.3pp | -59.0% |
| Current Ratio | 2.45-1.5x | 3.98-0.2x | 4.22+2.0x | 2.23-2.7x | 4.91-2.2x | 7.11-1.3x | 8.42-0.5x | 8.89+4.5x | 4.35-2.3x | 6.63-1.8x | 8.42+4.3x | 4.07-5.0x | 9.02+4.8x | 4.26-3.7x | 7.94 |
| Debt-to-Equity | 0.38+0.4x | 0.000.0x | 0.000.0x | 0.00-0.3x | 0.28+0.3x | 0.00-0.1x | 0.150.0x | 0.11 | N/A | N/A | 0.76+0.4x | 0.34-0.1x | 0.45-0.3x | 0.72+0.2x | 0.51 |
| FCF Margin | -59340.0% | -49710.0% | -606780.0% | -1007.8% | -16279.2% | -6679.1% | N/A | -34189.0% | -348.5% | -858.1% | N/A | N/A | N/A | -10048.9% | -5995.6% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Alaunos Therapeutics, Inc Ranks
Frequently Asked Questions
What is Alaunos Therapeutics, Inc's annual revenue?
Alaunos Therapeutics, Inc (TCRT) reported $5K in total revenue for fiscal year 2025. This represents a -50.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Alaunos Therapeutics, Inc's revenue growing?
Alaunos Therapeutics, Inc (TCRT) revenue declined by 50.0% year-over-year, from $10K to $5K in fiscal year 2025.
Is Alaunos Therapeutics, Inc profitable?
No, Alaunos Therapeutics, Inc (TCRT) reported a net income of -$4.2M in fiscal year 2025.
What is Alaunos Therapeutics, Inc's EBITDA?
Alaunos Therapeutics, Inc (TCRT) had EBITDA of -$4.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Alaunos Therapeutics, Inc's return on equity (ROE)?
Alaunos Therapeutics, Inc (TCRT) has a return on equity of -194.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Alaunos Therapeutics, Inc's free cash flow?
Alaunos Therapeutics, Inc (TCRT) recorded an outflow of $3.0M in free cash flow during fiscal year 2025. This represents a 40.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Alaunos Therapeutics, Inc's operating cash flow?
Alaunos Therapeutics, Inc (TCRT) recorded an outflow of $2.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Alaunos Therapeutics, Inc's total assets?
Alaunos Therapeutics, Inc (TCRT) had $3.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Alaunos Therapeutics, Inc's capital expenditures?
Alaunos Therapeutics, Inc (TCRT) invested $98K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Alaunos Therapeutics, Inc spend on research and development?
Alaunos Therapeutics, Inc (TCRT) invested $1.4M in research and development during fiscal year 2025.
What is Alaunos Therapeutics, Inc's current ratio?
Alaunos Therapeutics, Inc (TCRT) had a current ratio of 2.45 as of fiscal year 2025, which is generally considered healthy.
What is Alaunos Therapeutics, Inc's debt-to-equity ratio?
Alaunos Therapeutics, Inc (TCRT) had a debt-to-equity ratio of 0.38 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Alaunos Therapeutics, Inc's return on assets (ROA)?
Alaunos Therapeutics, Inc (TCRT) had a return on assets of -140.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Alaunos Therapeutics, Inc's cash runway?
Based on fiscal year 2025 data, Alaunos Therapeutics, Inc (TCRT) had $1.4M in cash against an annual operating cash burn of $2.9M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Alaunos Therapeutics, Inc's Altman Z-Score?
Alaunos Therapeutics, Inc (TCRT) has an Altman Z-Score of -437.27, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Alaunos Therapeutics, Inc's Piotroski F-Score?
Alaunos Therapeutics, Inc (TCRT) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Alaunos Therapeutics, Inc's earnings high quality?
Alaunos Therapeutics, Inc (TCRT) reported a net loss of $4.2M while operations used $2.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.